Rationalizing the approach to children with fever in neutropenia

Current Opinion in Infectious Diseases

Volumn 25, Issue 3, 2012, Pages 258-265

  Ammann, Roland A ^a   Tissing, Wim J E ^b   Phillips, Bob ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

cancer; childhood; fever in neutropenia; risk stratification; stepping down treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULPERAZON;

ARTHRALGIA; ARTHRITIS; ARTHROPATHY; CHILDHOOD CANCER; CHILDHOOD DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; HUMAN; LABORATORY TEST; META ANALYSIS (TOPIC); NONHUMAN; OUTPATIENT CARE; PATIENT SAFETY; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; REVIEW; SYSTEMATIC REVIEW (TOPIC); TENDINITIS;

ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; EVIDENCE-BASED MEDICINE; FEVER; HUMANS; NEOPLASMS; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT;

EID: 84861096688     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328351d199     Document Type: Review

References (55)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328-340.
2. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284:1061-1065.
3. Klastersky J, Paesmans M, Rubenstein EB, et al. TheMultinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-3051.
4. te Poele EM, Tissing WJ, Kamps WA, de Bont ES. Risk assessment in fever and neutropenia in children with cancer: What did we learn? Crit Rev Oncol Hematol 2009; 72:45-55.
5. Oude Nijhuis C, Kamps WA, Daenen SM, et al. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 2005; 23:7437-7444.
6. Melendez E, Harper MB. Risk of serious bacterial infection in isolated and unsuspected neutropenia. Acad Emerg Med 2010; 17:163-167.
7. Santolaya ME. Supportive care in children. Curr Opin Oncol 2010; 22:323-329.
8. Santolaya ME, Farfan MJ, De La Maza V, et al. Diagnosis of bacteremia in febrile neutropenic episodes in children with cancer: Microbiologic and molecular approach. Pediatr Infect Dis J 2011; 30:957-961. A large multicenter study comparing conventional blood cultures with PCR-based analysis of bacteremia in pediatric fever in neutropenia.
9. Sakaguchi S, Saito M, Tsuji H, et al. Bacterial rRNA-targeted reverse transcription- PCR used to identify pathogens responsible for fever with neutropenia. J Clin Microbiol 2010; 48:1624-1628.
10. Lamoth F, Jaton K, Prod'hom G, et al. Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia. J Clin Microbiol 2010; 48:3510-3516.
11. Lindblom A, Bhadri V, Sö derhäll S, et al. Respiratory viruses, a common microbiological finding in neutropenic children with fever. J Clin Virol 2010; 47:234-237.
12. Scheinemann K, Ethier MC, Dupuis LL, et al. Utility of peripheral blood cultures in bacteremic pediatric cancer patients with a central line. Support Care Cancer 2010; 18:913-919.
13. Phillips B, Wade R, Westwood M, et al. Systematic review and meta-analysis of the value of clinical features to exclude radiographic pneumonia in febrile neutropenic episodes in children and young people. J Paediatr Child Health 2011. doi: 10.1111/j.1440-1754.2011.02211.x. [Epub ahead of print]
14. Agrawal AK, Saini N, Gildengorin G, Feusner JH. Is routine computed tomographic scanning justified in the first week of persistent febrile neutropenia in children with malignancies? Pediatr Blood Cancer 2011; 57:620-624. A retrospective study shedding some light on one aspect of how to proceed diagnostically in neutropenia with prolonged fever.
15. Palazzi DL. The use of antimicrobial agents in children with fever during chemotherapy-induced neutropenia: The importance of risk stratification. Pediatr Infect Dis J 2011; 30:887-890.
16. Demir HA, Kutluk T, Ceyhan M, et al. Comparison of sulbactam-cefoperazone with carbapenems as empirical monotherapy for febrile neutropenic children with lymphoma and solid tumors. Pediatr Hematol Oncol 2011; 28:299-310.
17. Ichikawa M, Suzuki D, Ohshima J, et al. Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia. Pediatr Blood Cancer 2011; 57:1159-1162.
18. Manji A, Lehrnbecher T, Dupuis LL, et al. A meta-analysis of antipseudomonal penicillins and cephalosporins in pediatric patients with fever and neutropenia. Pediatr Infect Dis J 2011. doi: 10.1097/INF.0b013e318242590e. [Epub ahead of print]
19. Manji A, Lehrnbecher T, Dupuis LL, et al. A systematic review and metaanalysis of antipseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Support Care Cancer 2011. doi: 10.1007/s00520-011-1333-3. [Epub ahead of print] An instructive meta-analysis with the potential to change the common but not evidence-based practice to use carbapenems as first-line therapy in fever in neutropenia.
20. McCavit TL, Winick N. Time-to-antibiotic administration as a quality of care measure in children with febrile neutropenia: A survey of pediatric oncology centers. Pediatr Blood Cancer 2012; 58:303-305.
21. Phillips B, Wade R, Stewart LA, Sutton AJ. Systematic review and metaanalysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. Eur J Cancer 2010; 46:2950-2964. A large overview on and analysis of 16 risk prediction rules.
22. Phillips RJ, Sutton AJ, Riley RD, et al. On behalf of the PICNICC Collaboration. Predicting infectious complications in neutropenic children and young people with cancer (IPD Protocol). Syst Rev (in press). An interesting study protocol, regarding both the current knowledge of risk prediction in pediatric neutropenia, and the technique of individual patient data (IPD) meta-analysis.
23. Ammann RA, Bodmer N, Hirt A, et al. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: The prospective multicenter SPOG 2003 FN study. J Clin Oncol 2010; 28:2008-2014. A medium-sized multicenter study from Switzerland and Germany, developing a risk-prediction rule for adverse events in general, including internal cross-validation.
24. Agyeman P, Aebi C, Hirt A, et al. Predicting bacteremia in children with cancer and fever in chemotherapy-induced neutropenia: Results of the prospective multicenter SPOG 2003 FN study. Pediatr Infect Dis J 2011; 30:e114-e119. A medium-sized multicenter study from Switzerland and Germany, developing a risk-prediction rule for bacteremia, including internal cross-validation.
25. Villarroel M, Aviles CL, Silva P, et al. Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia: A prospective multicenter evaluation. Pediatr Infect Dis J 2010; 29:816-821. A large-sized study developing a prediction rule for invasive fungal disease, without validation.
26. Hakim H, Flynn PM, Srivastava DK, et al. Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2010; 29:53-59.
27. Macher E, Dubos F, Garnier N, et al. Predicting the risk of severe bacterial infection in children with chemotherapy-induced febrile neutropenia. Pediatr Blood Cancer 2010; 55:662-667. A retrospective study externally validating the performance of six published prediction rules in 377 fever in neutropenia episodes from two centers.
28. Miedema KG, de Bont ES, Oude Nijhuis CS, et al. Validation of a new risk assessment model for predicting adverse events in children with fever and chemotherapy-induced neutropenia. J Clin Oncol 2011; 29:e182-e184. A retrospective study externally validating the performance of a recently published prediction rule [23 & ] in 210 fever in neutropenia episodes
29. Asturias EJ, Corral JE, Quezada J. Evaluation of six risk factors for the development of bacteremia in children with cancer and febrile neutropenia. Curr Oncol 2010; 17:59-63.
30. Badiei Z, Khalesi M, Alami MH, et al. Risk factors associated with lifethreatening infections in children with febrile neutropenia: A data mining approach. J Pediatr Hematol Oncol 2011; 33:e9-e12.
31. El-Mahallawy HA, El-Wakil M, Moneer MM, Shalaby L. Antibiotic resistance is associated with longer bacteremic episodes and worse outcome in febrile neutropenic children with cancer. Pediatr Blood Cancer 2011; 57:283-288.
32. Hatzistilianou M, Rekliti A, Athanassiadou F, Catriu D. Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res 2010; 59:339-347.
33. Miedema KG, de Bont ES, Elferink RF, et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer 2011; 19:1593-1600.
34. Semeraro M, Thomee C, Rolland E, et al. A predictor of unfavourable outcome in neutropenic paediatric patients presenting with fever of unknown origin. Pediatr Blood Cancer 2010; 54:284-290.
35. Hodge G, Scott J, Osborn M, et al. Increased T regulatory cells and decreased Th1 pro-inflammatory cytokines correlate with culture-positive infection in febrile neutropenia childhood oncology patients. Cytokine 2011; 53:286-288.
36. Tang Y, Liao C, Xu X, et al. Th1/Th2 Cytokine profiles in G+/G- bacteremia in pediatric hematology/oncology patients. Pediatr Blood Cancer 2012; 58:50-54.
37. Phillips R, Wade R, Lehrnbecher T, et al. The value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer: A systematic review and meta-analysis. BMC Med 2012; 10:6. A meta-analysis condensing the evidence from 25 biomarker studies in pediatric fever in neutropenia.
38. Gea-Banacloche J. Biomarkers in fever and neutropenia: A solution in search of a problem? Crit Care Med 2011; 39:1205-1206. A concise and deliberately provocative editorial on the value of nonstandard laboratory characteristics in risk prediction.
39. Teuffel O, Sung L. Advances in management of low-risk febrile neutropenia. Curr Opin Pediatr 2012; 24:40-45.
40. Brack E, Bodmer N, Simon A, et al. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatr Blood Cancer 2012. doi: 10.1002/pbc.24076. [Epub ahead of print] First RCT applying noninferiority tests for safety and efficacy of stepping-down treatment in pediatric low-risk fever in neutropenia.
41. Teuffel O, Ethier MC, Alibhai SM, et al. Outpatient management of cancer patients with febrile neutropenia: A systematic review and meta-analysis. Ann Oncol 2011; 22:2358-2365. A meta-analysis on safety and efficacy of stepping down from standard treatment at different time points.
42. Sung L, Manji A, Beyene J, et al. Fluoroquinolones in children with fever and neutropenia: A systematic review of prospective trials. Pediatr Infect Dis J 2011. doi: 10.1097/INF.0b013e318245ab48. [Epub ahead of print] A large meta-analysis on efficacy and short-term safety of using ciprofloxacin and other fluoroquinolones in low-risk fever in neutropenia.
43. Lüthi F, Leibundgut K, Niggli FK, et al. Serious medical complications in children with cancer and fever in chemotherapy-induced neutropenia: Results of the prospective multicenter SPOG 2003 FN study. Pediatr Blood Cancer 2011. doi: 10.1002/pbc.23277. [Epub ahead of print]
44. Teuffel O, Amir E, Alibhai SM, et al. Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer. Pediatrics 2011; 127:e279-e286. An instructive cost-effectiveness analysis, considering utility with a concept comparable to quality-adjusted life-years, with sensitivity analyses, but still understandable for the nonstatistician.
45. Cheng S, Teuffel O, Ethier MC, et al. Health-related quality of life anticipated with different management strategies for paediatric febrile neutropaenia. Br J Cancer 2011; 105:606-611. A single-center study asking parents and patients on their anticipated quality of life, and on their preference among four different treatment regimens for low-risk fever in neutropenia.
46. Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29:415-420. A high-quality large multicenter RCT on empirical antifungal therapy in prolonged fever in neutropenia.
47. Blyth CC, Hale K, Palasanthiran P, et al. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev 2010:CD006343. An extensive review and meta-analysis on the efficacy and safety of empirically used antifungals in prolonged fever in neutropenia.
48. Atay D, Ozturk G, Akcay A, et al. Effect and safety of granulocyte transfusions in pediatric patients with febrile neutropenia or defective granulocyte functions. J Pediatr Hematol Oncol 2011; 33:e220-e225.
49. de Naurois J, Novitzky-Basso I, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 (Suppl 5):v252-v256. The current European evidence-based guidelines for the management of fever in neutropenia in adults.
50. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56-e93. The current US evidence-based guidelines for the management of fever in neutropenia in adults.
51. Comité Nacional de Infectiologia Pediatrica. [Consensus on management of children with cancer, neutropenia and fever: Update 2008-2009]. Arch Argent Pediatr 2010; 108:e47-e70.
52. Giurici N, Zanazzo GA. Consensus on diagnosis and empiric antibiotic therapy of febrile neutropenia. Pediatr Rep 2011; 3:e4.
53. Pakakasama S, Surayuthpreecha K, Pandee U, et al. Clinical practice guideline for children with cancer presenting with fever at emergency room. Pediatr Int 2011; 53:902-905.
54. Sung L, Phillips R, Lehrnbecher T. Time for paediatric febrile neutropenia guidelines - children are not little adults. Eur J Cancer 2011; 47:811-813. A brief comment underlining the need for pediatric fever in neutropenia guidelines.
55. Castagnola E, Caviglia I, Haupt R. Guidelines for the management of bacterial and fungal infections during chemotherapy for pediatric acute leukemia or solid tumors: What is available in 2010? Pediatr Rep 2011; 3:e7.